Lauren Dembeck

A triple medication combination could be life-changing for the majority of patients with cystic fibrosis.

While investigations are ongoing, an interim report offers clinical guidance regarding vaping-associated lung injuries.

Patients with cystic fibrosis show transcriptomic changes after starting treatment with lumacaftor/ivacaftor.

Treated immune cells function properly to kill more bacteria, depending on the treatment and the bacteria.